These results demonstrate that treatment of tumors with RdB/IL12/shVEGF tumors can induce high expression of IFN-γ and subsequently attenuate VEGF expression in tumor tissue, resulting in a shift in the T cell response toward the type 1 pattern for enhanced antitumor efficacy. The gene discussed is IFNG; the disease is neoplasm.